Biomarkers of Inflammation in Inflammatory Bowel Disease

Gastroenterology

Volumn 149, Issue 5, 2015, Pages 1275-1285.e2

  Sands, Bruce E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; C Reactive Protein; Calprotectin; Crohn's Disease; Ulcerative Colitis

Indexed keywords

ADENOSINE DEAMINASE; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 12; C REACTIVE PROTEIN; CALGRANULIN; CERULOPLASMIN; ELASTASE; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHIL PROTEIN X; FERRITIN; FIBRINOGEN; GELATINASE B; GLUCOCORTICOID; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LACTOFERRIN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MICRORNA; MYELOPEROXIDASE; NEOPTERIN; PROTHROMBIN; SERUM AMYLOID A; SIALIC ACID; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ARTICLE; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DISEASE ACTIVITY; FECES ANALYSIS; GENE EXPRESSION; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; IRRITABLE COLON; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEOMICS; RELAPSE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FECES; IRRITABLE BOWEL SYNDROME; METABOLISM; PATHOLOGY; PROCEDURES; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

BIOMARKERS; C-REACTIVE PROTEIN; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FECES; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; METABOLOMICS; PROGNOSIS; PROTEOMICS; SENSITIVITY AND SPECIFICITY;

EID: 84940969366     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.07.003     Document Type: Article

References (86)

1. L. Peyrin-Biroulet, W. Reinisch, J.F. Colombel, and et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial Gut 63 2014 88 95
2. P. Rutgeerts, W.J. Sandborn, B.G. Feagan, and et al. Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 353 2005 2462 2476
3. S. Vermeire, G. Van Assche, and P. Rutgeerts Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 55 2006 426 431
4. M. Cioffi, A.D. Rosa, R. Serao, and et al. Laboratory markers in ulcerative colitis: current insights and future advances World J Gastrointest Pathophysiol 6 2015 13 22
5. I. Maor, T. Rainis, A. Lanir, and et al. Adenosine deaminase activity in patients with Crohn's disease: distinction between active and nonactive disease Eur J Gastroenterol Hepatol 23 2011 598 602
6. D. Diaz-Jimenez, L.E. Nunez, C.J. Beltran, and et al. Soluble ST2: a new and promising activity marker in ulcerative colitis World J Gastroenterol 17 2011 2181 2190
7. N.K. Gupta, A.I. Thaker, N. Kanuri, and et al. Serum analysis of tryptophan catabolism pathway: correlation with Crohn's disease activity Inflamm Bowel Dis 18 2012 1214 1220
8. J.L. Mendoza, and M.T. Abreu Biological markers in inflammatory bowel disease: Practical consideration for clinicians Gastroenterologie Clinique Et Biologique 33 2009 S158 S173
9. L. Peyrin-Biroulet, F. Gonzalez, L. Dubuquoy, and et al. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease Gut 61 2012 78 85
10. S.P. Travis, J.M. Farrant, C. Ricketts, and et al. Predicting outcome in severe ulcerative colitis Gut 38 1996 905 910
11. J.S. Danik, and P.M. Ridker Genetic determinants of C-reactive protein Curr Atheroscler Rep 9 2007 195 203
12. S. Vermeire, G. Van Assche, and P. Rutgeerts C-reactive protein as a marker for inflammatory bowel disease Inflamm Bowel Dis 10 2004 661 665
13. D. Foell, H. Wittkowski, and J. Roth Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage Gut 58 2009 859 868
14. G. Chung-Faye, B. Hayee, S. Maestranzi, and et al. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation Inflamm Bowel Dis 13 2007 1374 1378
15. T. Aomatsu, H. Imaeda, K. Matsumoto, and et al. Faecal chitinase 3-like-1: a novel biomarker of disease activity in paediatric inflammatory bowel disease Aliment Pharmacol Ther 34 2011 941 948
16. F.S. Lehmann, E. Burri, and C. Beglinger The role and utility of faecal markers in inflammatory bowel disease Therap Adv Gastroenterol 8 2015 23 36
17. A. Lasson, P.O. Stotzer, L. Ohman, and et al. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis J Crohns Colitis 9 2015 26 32
18. J.L. Cracowski, B. Bonaz, G. Bessard, and et al. Increased urinary F-2-isoprostanes in patients with Crohn's disease American Journal of Gastroenterology 97 2002 99 103
19. J.C. Johnson, C.R. Schmidt, M.J. Shrubsole, and et al. Urine PGE-M: A metabolite of prostaglandin E-2 as a potential biomarker of advanced colorectal neoplasia Clin Gastroenterol Hepatol 4 2006 1358 1365
20. F. Stanke-Labesque, J. Pofelski, A. Moreau-Gaudry, and et al. Urinary leukotriene E-4 excretion: A biomarker of inflammatory bowel disease activity Inflam Bowel Dis 14 2008 769 774
21. Y. Arai, S. Arihiro, T. Matsuura, and et al. Prostaglandin E-major urinary metabolite as a reliable surrogate marker for mucosal inflammation in ulcerative colitis Inflam Bowel Dis 20 2014 1208 1216
22. D. Bolignano, A. Della Torre, A. Lacquaniti, and et al. Neutrophil gelatinase-associated lipocalin levels in patients with Crohn disease undergoing treatment with infliximab J Invest Med 58 2010 569 571
23. L. Marko, N. Szigeti, Z. Szabo, and et al. Potential urinary biomarkers of disease activity in Crohn's disease Scand J Gastroenterol 45 2010 1440 1448
24. S. Nancey, A. Perret-Liaudet, D. Moussata, and et al. Urinary neopterin is a valuable tool in monitoring Crohn's disease activity Inflam Bowel Dis 14 2008 1548 1554
25. S.B. Menees, C. Powell, J. Kurlander, and et al. A meta-analysis of the utility of c-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS Am J Gastroenterol 110 2015 444 454
26. P.F. van Rheenen, E. Van de Vijver, and V. Fidler Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis BMJ 341 2010 c3369
27. V. Kristensen, and B. Moum Correspondence: fecal calprotectin and cut-off levels in inflammatory bowel disease Scand J Gastroenterol 2015 1 2
28. P. Henderson, N.H. Anderson, and D.C. Wilson The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis Am J Gastroenterol 109 2014 637 645
29. J. Jones, E.V. Loftus, R. Panaccione, and et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease Clin Gastroenterol Hepatol 6 2008 1218 1224
30. G. D'Haens, M. Ferrante, S. Vermeire, and et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease Inflamm Bowel Dis 18 2012 2218 2224
31. T. Sipponen, E. Savilahti, K.L. Kolho, and et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings Inflamm Bowel Dis 14 2008 40 46
32. A. Lasson, M. Simren, P.O. Stotzer, and et al. Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis Inflamm Bowel Dis 19 2013 576 581
33. D.R. Gaya, T.D. Lyon, A. Duncan, and et al. Faecal calprotectin in the assessment of Crohn's disease activity QJM 98 2005 435 441
34. T. Lobaton, A. Lopez-Garcia, F. Rodriguez-Moranta, and et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease J Crohns Colitis 7 2013 e641 651
35. A.M. Schoepfer, C. Beglinger, A. Straumann, and et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger index, C-reactive protein, platelets, hemoglobin, and blood leukocytes Inflam Bowel Dis 19 2013 332 341
36. A.M. Schoepfer, C. Beglinger, A. Straumann, and et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI Am J Gastroenterol 105 2010 162 169
37. J. Guardiola, T. Lobaton, L. Rodriguez-Alonso, and et al. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission Clin Gastroenterol Hepatol 12 2014 1865 1870
38. T. Sipponen, J. Haapamaki, E. Savilahti, and et al. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy Scand J Gastroenterol 47 2012 778 784
39. I.K. Onal, Y. Beyazit, B. Sener, and et al. The value of fecal calprotectin as a marker of intestinal inflammation in patients with ulcerative colitis Turk J Gastroenterol 23 2012 509 514
40. S. Samuel, D.H. Bruining, E.V. Loftus Jr., and et al. Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy Clin Gastroenterol Hepatol 10 2012 1253 1259
41. W.A. Faubion Jr., J.G. Fletcher, S. O'Byrne, and et al. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging Am J Gastroenterol 108 2013 1891 1900
42. K.L. Kolho, T. Raivio, H. Lindahl, and et al. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease Scand J Gastroenterol 41 2006 720 725
43. T. Sipponen, C.G. Bjorkesten, M. Farkkila, and et al. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment Scand J Gastroenterol 45 2010 325 331
44. M.T. Osterman, F.N. Aberra, R. Cross, and et al. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis Clin Gastroenterol Hepatol 12 2014 1887-U1369
45. M. De Vos, O. Dewit, G. D'Haens, and et al. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naive patients with ulcerative colitis J Crohns Colitis 6 2012 557 562
46. D.T. Rubin, P. Mulani, J.D. Chao, and et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: Results from the CHARM trial Inflam Bowel Dis 18 2012 818 825
47. F. Cornillie, S.B. Hanauer, R.H. Diamond, and et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial Gut 63 2014 1721 1727
48. D. Wolf, and C. Wolf Improvement of C-reactive protein in certolizumab pegol responders, but not in non-responders in Crohn's disease Am J Gastroenterol 109 2014 S523-S523
49. B.E. Sands, B.G. Feagan, P. Rutgeerts, and et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed Gastroenterology 147 2014 618
50. S.R. Targan, B.G. Feagan, R.N. Fedorak, and et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial Gastroenterology 132 2007 1672 1683
51. G. Monteleone, M.F. Neurath, S. Ardizzone, and et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease N Engl J Med 372 2015 1104 1113
52. F. Costa, M.G. Mumolo, L. Ceccarelli, and et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease Gut 54 2005 364 368
53. R. D'Inca, E. Dal Pont, V. Di Leo, and et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 103 2008 2007 2014
54. A. Diamanti, F. Colistro, M.S. Basso, and et al. Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases Inflamm Bowel Dis 14 2008 1229 1235
55. D. Walkiewicz, S.L. Werlin, D. Fish, and et al. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease Inflamm Bowel Dis 14 2008 669 673
56. T. Sipponen, and K.L. Kolho Faecal calprotectin in children with clinically quiescent inflammatory bowel disease Scand J Gastroenterol 45 2010 872 877
57. J.P. Gisbert, F. Bermejo, J.L. Perez-Calle, and et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse Inflamm Bowel Dis 15 2009 1190 1198
58. V. Garcia-Sanchez, E. Iglesias-Flores, R. Gonzalez, and et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J Crohns Colitis 4 2010 144 152
59. L. Kallel, I. Ayadi, S. Matri, and et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study Eur J Gastroenterol Hepatol 22 2010 340 345
60. D. Laharie, S. Mesli, F. El Hajbi, and et al. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study Aliment Pharmacol Ther 34 2011 462 469
61. M.A. Meuwis, G. Vernier-Massouille, J.C. Grimaud, and et al. Serum calprotectin as a biomarker for Crohn's disease J Crohns Colitis 7 2013 e678 e683
62. T. Yamamoto, M. Shiraki, T. Bamba, and et al. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy Int J Colorectal Dis 29 2014 485 491
63. M. De Vos, E.J. Louis, J. Jahnsen, and et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy Inflamm Bowel Dis 19 2013 2111 2117
64. R. Mao, Y.L. Xiao, X. Gao, and et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies Inflamm Bowel Dis 18 2012 1894 1899
65. M. Regueiro, K.E. Kip, W. Schraut, and et al. Crohn's disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection Inflamm Bowel Dis 17 2011 118 126
66. C.A. Lamb, M.K. Mohiuddin, J. Gicquel, and et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease Br J Surg 96 2009 663 674
67. M. Scarpa, R. D'Inca, D. Basso, and et al. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease Dis Colon Rectum 50 2007 861 869
68. A. Orlando, I. Modesto, F. Castiglione, and et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound Eur Rev Med Pharmacol Sci 10 2006 17 22
69. G. Boschetti, M. Laidet, D. Moussata, and et al. Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with crohn's disease Am J Gastroenterol 110 2015 865 872
70. P. De Cruz, M.A. Kamm, A.L. Hamilton, and et al. Crohn's disease management after intestinal resection: a randomised trial Lancet 385 2014 1406 1417
71. E.K. Wright, M.A. Kamm, P. De Cruz, and et al. Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn's Disease After Surgery Gastroenterology 48 2015 938 947
72. J.T. Bjerrum, M. Hansen, J. Olsen, and et al. Genome-wide gene expression analysis of mucosal colonic biopsies and isolated colonocytes suggests a continuous inflammatory state in the lamina propria of patients with quiescent ulcerative colitis Inflamm Bowel Dis 16 2010 999 1007
73. R. Burakoff, V. Pabby, L. Onyewadume, and et al. Blood-based biomarkers used to predict disease activity in Crohn's disease and ulcerative colitis Inflamm Bowel Dis 21 2015 1132 1140
74. M. Coskun, J.T. Bjerrum, J.B. Seidelin, and et al. miR-20b, miR-98, miR-125b-1∗, and let-7e∗as new potential diagnostic biomarkers in ulcerative colitis World J Gastroenterol 19 2013 4289 4299
75. A.M. Zahm, M. Thayu, N.J. Hand, and et al. Circulating microRNA is a biomarker of pediatric Crohn Disease J Pediatr Gastroenterol Nutr 53 2011 26 33
76. F. Wu, N.J. Guo, H. Tian, and et al. Peripheral blood microRNAs distinguish active ulcerative colitis and Crohn's disease Inflamm Bowel Dis 17 2011 241 250
77. J.R. Marchesi, E. Holmes, F. Khan, and et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease J Prot Res 6 2007 546 551
78. J.T. Bjerrum, O.H. Nielsen, F.H. Hao, and et al. Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology J Prot Res 9 2010 954 962
79. N.R. Patel, M.J.W. McPhail, M.I.F. Shariff, and et al. Biofluid metabonomics using H-1 NMR spectroscopy: the road to biomarker discovery in gastroenterology and hepatology Expert Rev Gastroenterol Hepatol 6 2012 239 251
80. M. Storr, H.J. Vogel, and R. Schicho Metabolomics: is it useful for inflammatory bowel diseases? Curr Opin Gastroenterol 29 2013 378 383
81. M. Kohashi, S. Nishiumi, M. Ooi, and et al. A novel gas chromatography mass spectrometry-based serum diagnostic and assessment approach to ulcerative colitis J Crohns Colitis 8 2014 1010 1021
82. N. Patel, N. Alkhouri, K. Eng, and et al. Metabolomic analysis of breath volatile organic compounds reveals unique breathprints in children with inflammatory bowel disease: a pilot study Aliment Pharmacol Ther 40 2014 498 507
83. N.Y. Han, E.H. Kim, J. Choi, and et al. Quantitative proteomic approaches in biomarker discovery of inflammatory bowel disease J Dig Dis 13 2012 497 503
84. N.A. Poulsen, V. Andersen, J.C. Moller, and et al. Comparative analysis of inflamed and non-inflamed colon biopsies reveals strong proteomic inflammation profile in patients with ulcerative colitis BMC Gastroenterol 12 2012 76
85. M.A. Meuwis, M. Fillet, L. Lutteri, and et al. Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study Clin Biochem 41 2008 960 967
86. N. Li, X.M. Wang, Y.F. Zhang, and et al. Comparative proteomics analysis of serum proteins in ulcerative colitis patients Mol Biol Rep 39 2012 5659 5667